Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.

Objective: Determine if sublingual dexmedetomidine, a selective α2 adrenergic receptor agonist, reduces symptoms of acute agitation associated with schizophrenia or schizoaffective disorder. Methods: This phase 3, randomized, double-blind, placebo-controlled study was conducted in adults diagnosed with schizophrenia or schizoaffective disorder per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. The study was conducted at 15 US sites between January 23, 2020, and May 8, 2020. Participants were randomized to sublingual dexmedetomidine 180 μg, 120 μg, or matching placebo. The primary efficacy endpoint was mean change from baseline in the Positive and Negative Syndrome Scale-Excited Component (PEC) total score at 2 hours postdose. Results: Altogether, 380 participants (mean age 45.6 years, 63.4% identifying as male, 77.9% identifying as Black or African American) were randomized; 380 (100%) self-administered study medication, and 372 (97.9%) completed the study. The mean PEC total score at baseline (17.6) indicated mild to moderate agitation. At 2 hours postdose, the least squares mean changes (SE) from baseline were -10.3 (0.4) for sublingual dexmedetomidine 180 μg, -8.5 (0.4) for 120 μg, and -4.8 (0.4) for placebo. Least squares mean differences (97.5% confidence intervals) in the sublingual dexmedetomidine groups were -5.5 (-6.7 to -4.3) for 180 μg and -3.7 (-4.9 to -2.5) for 120 μg (both P < .001 vs placebo). The most commonly encountered adverse events with dexmedetomidine (incidence ≥ 5% and ≥ 2× rate observed with placebo) were somnolence, dry mouth, and hypotension for the 120 μg dose, and somnolence, dizziness, orthostatic hypotension, and oral hypoesthesia for the 180 μg dose. Conclusions: Treatment with sublingual dexmedetomidine 180 μg or 120 μg was more efficacious than placebo in reducing acute agitation associated with schizophrenia as measured by PEC scores at 2 hours postdose. Trial Registration: ClinicalTrials.gov identifier: NCT04268303.

[1]  M. Fava,et al.  Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. , 2022, JAMA.

[2]  M. Pompili,et al.  The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review , 2021, International journal of environmental research and public health.

[3]  L. Citrome,et al.  Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults , 2019, Neuropsychiatric disease and treatment.

[4]  S. Kaiser,et al.  Effects of Seclusion and Restraint in Adult Psychiatry: A Systematic Review , 2019, Front. Psychiatry.

[5]  T. Steinert,et al.  Physical Harm and Death in the Context of Coercive Measures in Psychiatric Patients: A Systematic Review , 2019, Front. Psychiatry.

[6]  A. Lingford-Hughes,et al.  Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation , 2018, Journal of psychopharmacology.

[7]  D. Judge,et al.  Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia , 2018, BMC Psychiatry.

[8]  L. San,et al.  State of Acute Agitation at Psychiatric Emergencies in Europe: The STAGE Study , 2016, Clinical practice and epidemiology in mental health : CP & EMH.

[9]  K. Dwan,et al.  Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta‐analysis , 2016, Human psychopharmacology.

[10]  L. Citrome,et al.  Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting , 2016, The western journal of emergency medicine.

[11]  H. Möller,et al.  Assessment and management of agitation in psychiatry: Expert consensus , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[12]  M. Casavant,et al.  The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project BETA psychopharmacology workgroup. , 2012, The western journal of emergency medicine.

[13]  S. Zeller,et al.  Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup , 2012, The western journal of emergency medicine.

[14]  S. Zeller,et al.  Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation , 2012, The western journal of emergency medicine.

[15]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[16]  L. San,et al.  Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room , 2011, Health and quality of life outcomes.

[17]  L. Citrome Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. , 2007, The Journal of clinical psychiatry.

[18]  S. Targum,et al.  The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[19]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[20]  M. Crowe,et al.  What Events Precede Violent Incidents in Psychiatric Hospitals? , 1994, British Journal of Psychiatry.